The time to the recurrence differed depending on the biological subtype: in the two patients with the luminal A subtype (ER/PR+HER2−Ki-67 ≤ 20%), it was 66 and 108 months, while in the two patients with HER2-positive breast cancer, it was 19 and 29 months. This evidence concerns the gene ERBB2 and breast carcinoma.